Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W T Beck

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Molecular Pharmacology|January 29, 2000
Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responsesS E Morgan, R S Cadena, S C Raimondi, et al.
Cancer Research|May 1, 1989
Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cellsJ S Wolverton, M K Danks, C A Schmidt, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1983
Why is tumor tRNA hypomodified with respect to Q nucleoside?J R Katze, W T Beck, C S Cheng, et al.
Molecular Pharmacology|October 1, 1995
A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell lineU G Bhat, M A Winter, H L Pearce, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1991
Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposideB Y Bugg, M K Danks, W T Beck, et al.
Cancer Communications|January 1, 1989
Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposideM K Danks, C A Schmidt, D A Deneka, et al.
Cancer Research|July 1, 1985
Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cellsM K Danks, D W Metzger, R A Ashmun, et al.
Journal of Medicinal Chemistry|August 25, 2001
Synthesis and in vitro antitumor activity of oligonucleotide-tethered and related platinum complexesL Cai, K Lim, S Ren, et al.
Journal of Pharmaceutical Sciences|November 1, 1977
Synthesis and anticancer activity of novel cyclic N-hydroxyureasJ T Chou, W T Beck, T Khwaja, et al.
Cancer Research|February 1, 1986
Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamilW T Beck, M C Cirtain, A T Look, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Molecular Pharmacology|January 29, 2000
Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responsesS E Morgan, R S Cadena, S C Raimondi, et al.
Cancer Research|May 1, 1989
Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cellsJ S Wolverton, M K Danks, C A Schmidt, et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|January 1, 1983
Why is tumor tRNA hypomodified with respect to Q nucleoside?J R Katze, W T Beck, C S Cheng, et al.
Molecular Pharmacology|October 1, 1995
A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell lineU G Bhat, M A Winter, H L Pearce, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 1, 1991
Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposideB Y Bugg, M K Danks, W T Beck, et al.
Cancer Communications|January 1, 1989
Increased ATP requirement for activity of and complex formation by DNA topoisomerase II from human leukemic CCRF-CEM cells selected for resistance to teniposideM K Danks, C A Schmidt, D A Deneka, et al.
Cancer Research|July 1, 1985
Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cellsM K Danks, D W Metzger, R A Ashmun, et al.
Journal of Medicinal Chemistry|August 25, 2001
Synthesis and in vitro antitumor activity of oligonucleotide-tethered and related platinum complexesL Cai, K Lim, S Ren, et al.
Journal of Pharmaceutical Sciences|November 1, 1977
Synthesis and anticancer activity of novel cyclic N-hydroxyureasJ T Chou, W T Beck, T Khwaja, et al.
Cancer Research|February 1, 1986
Reversal of Vinca alkaloid resistance but not multiple drug resistance in human leukemic cells by verapamilW T Beck, M C Cirtain, A T Look, et al.
Pageof 11